Eli Lilly is scheduled to report its fourth-quarter results before the market opens Wednesday. Here is what you need to know. PROFIT: Analysts polled by FactSet expect the company to post net income ...

Novo Nordisk's stock plummets over 13% after the company warns of potential sales and profit declines in 2026, facing increasing competition in the weight-loss market, particularly from Eli Lilly's ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key ...

An analyst says Eli Lilly's Zepbound still looks like the heavyweight in weight loss compared to Pfizer's injection.

By Jacob Gronholt-Pedersen and Maggie Fick COPENHAGEN, Feb 3 (Reuters) - Wegovy maker Novo Nordisk warned on Tuesday that ...

Novo Noranisisk A/S shocked investors by forecasting a steep decline in sales this year, a sign of how intensifying price wars in obesity drugs and the Trump administration’s pressure on ...

Novo Nordisk's stock plunged Tuesday after the maker of diabetes and weight-loss drugs Ozempic and Wegovy said it expects ...

Novo Nordisk has launched a pill version of its blockbuster weight-loss drug, Wegovy. Novo Nordisk's stock plunged Tuesday ...

Novo Nordisk A/S reports fourth-quarter results on Wednesday, with investors eager to see whether the Danish drugmaker can demonstrate progress in stemming market share losses to rival Eli Lilly in ...

Novo Nordisk is scheduled to report results for the fourth quarter on Wednesday. Here is what you need to know: PROFIT FORECAST: Net profit is expected to fall 9.6% to 25.52 billion Danish kroner ...